MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer

Overview

The investigators propose to evaluate the feasibility, safety, and preliminary efficacy of delivering online, adaptive magnetic resonance imaging (MRI)-guided and gated stereotactic body radiation therapy for patients with recurrent or metastatic ovarian cancer on a novel, integrated Co-60 MRI treatment machine. To best assess this technology, the investigators will focus on patients that have no more than three sites of progressive disease within the central thorax, liver, and/or non-liver abdominopelvis to receive adaptive, MRI-guided and gated SBRT with MRI simulation. Patients will be treated in five fractions over one to two weeks. By adhering to strict normal tissue constraints, expected toxicity will be within the current standard of care but will allow adaptation based on daily anatomic changes. The prescription dose will be determined based on hard normal tissue constraints, and capped at 10Gy per fraction. Although the long term goal will be to achieve improved local control and disease-free survival with reduced toxicity, the present study will be driven by the short term goal of demonstrating the feasibility of this novel treatment approach for recurrent or metastatic ovarian cancer.

Full Title of Study: “Pilot Study of MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 14, 2018

Interventions

  • Device: MRI-guided SBRT
  • Behavioral: EORTC QLQ-C30 Questionnaire
    • 30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
  • Behavioral: EORTC QLQ-OV28 Questionnaire
    • 28 questions having answers that range from 1 (not at all) to 4 (very much)

Arms, Groups and Cohorts

  • Experimental: Arm 1: MRI-guided SBRT
    • Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments. Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV. All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site

Clinical Trial Outcome Measures

Primary Measures

  • Feasibility of providing online, adaptive MRI-guided and gated SBRT as measured by the ability to deliver a full course of MRI-guided SBRT in at least 80% of eligible patients who have completed simulation and planning
    • Time Frame: Completion of all enrolled patients (up to 2 years)

Secondary Measures

  • Safety as measured by acute toxicities
    • Time Frame: Up to 90 days post completion of treatment
    • the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.
  • Safety as measured by late toxicities
    • Time Frame: 91 days to 6 months post completion of treatment
    • the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.
  • Response rate
    • Time Frame: 3 months post treatment
    • -Response will be measured using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [Eur J Ca 45:228-247, 2009].
  • In-field control rate
    • Time Frame: 6 months post treatment
  • Local control rate
    • Time Frame: 3 months post treatment
  • Regional control rate
    • Time Frame: 3 months post treatment
  • Distant control rate
    • Time Frame: 3 months post treatment
  • Progression-free survival (PFS) rate
    • Time Frame: 6 months post treatment
    • -PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
  • Disease-free survival (DFS) rate
    • Time Frame: 6 months post treatment
    • -The length of time that a patient survives without any signs or symptoms of their cancer
  • Overall survival (OS) rate
    • Time Frame: 6 months post treatment
  • Patient-reported health-related quality of life (HRQOL)
    • Time Frame: 6 months post treatment
    • HRQOL will be measured using the EORTC QLQ-C30 and QLQ-OV28 questionnaires. European Organization for Research and Treatment of Cancer (EORTC) QLQ-30 consists of 28 questions with answers that range from 1 (Not At All) to 4 (Very Much) and 2 questions that range from 1 (Very Poor) to 7 (Excellent) EORTC QLQ-OV28 consists of 28 questions ranging with answers from 1 (Not At All) to 4 (Very Much)
  • CA-125 response levels
    • Time Frame: 6 months post treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically or cytologically confirmed primary disease histology of solid ovarian, fallopian tube, or primary peritoneal tumor categorization. – Deemed medically fit for stereotactic body radiation therapy by the treating physician. – At least 18 years old. – Karnofsky Performance Status ≥ 70 – Completed any systemic therapy (excluding endocrine therapy, which may be ongoing) at least one week prior to planned start of SBRT (two weeks preferred) and must have no plans to initiate systemic therapy for at least one week following end of SBRT (two weeks preferred). – Able to understand and be willing to sign an IRB approved written informed consent document (or legally authorized representative, if applicable). Exclusion Criteria:

  • Past history of radiotherapy within the projected treatment field of any of the disease sites to be treated by MRI-guided, gated, and/or online adaptive SBRT – Current central nervous systemic disease. – Widespread progressive disease, i.e., more than three sites of progressive disease (note that more than three sites of disease are permitted provided there are no more than three sites of progressive disease). – Actively receiving any investigational agents. – Presence of uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. – Pregnant and/or breastfeeding. Patients of childbearing potential must have a negative pregnancy test within 14 days of study entry. – Medical contraindication to undergoing MR imaging.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Washington University School of Medicine
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Clifford Robinson, M.D., Principal Investigator, Washington University School of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.